Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Needle-Syringe Clear all

Conditions: Macular Edema, Fibrosis of the Retina
Interventions: Ozurdex, Surgery, Anterior Chamber (AC) Tap; Drug · Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: IV Drug Usage, HIV Infections, Hepatitis C
Interventions: Tele-Harm Reduction, off-site linkage; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Miami, Florida • Tampa, Florida

Conditions: IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
Interventions: Atacicept 150 mg; Drug
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Vitiligo
Interventions: Needling, Triamcinolone; Procedure · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Pancreas, Mass Lesion
Interventions: Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe), Saline; Combination Product · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Influenza Infection
Interventions: VRC-FLUNPF099-00-VP (H1ssF_3928); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rhegmatogenous Retinal Detachment - Macula Off
Interventions: ONL1204 Ophthalmic Solution, Sham treatment; Drug
Lead sponsor: ONL Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more

Conditions: Breast Cancer, Ovarian Cancer, Colon Cancer, Benign Disease
Interventions: Tear collection; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Anesthesia
Interventions: Dental local anesthesia; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 4 Years to 10 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Interventions: VRC-HIVRGP096-00-VP, Alum Adjuvant; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Overweight
Interventions: NNC0113-5840, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Diabetic Macular Edema
Interventions: Vamikibart, Ranibizumab, Sham Procedure; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 36
States / cities: Arcadia, California • Poway, California • Sacramento, California + 33 more

Conditions: Malaria
Interventions: D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Rotator Cuff Tear
Interventions: Platelet Rich Plasma (PRP), Corticosteroid; Biological · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pancreatic Carcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer, Pancreatic Cancer, Adult
Interventions: Celiac Plexus Neurolysis, Radiofrequency Ablation; Other
Lead sponsor: AdventHealth; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Pulp Disease, Dental
Interventions: GentleWave®, EdgePRO™, Fotona LightWalker®, Conventional Needle Irrigation; Device
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Disorder of Soft Tissue of Body Wall Region
Interventions: Adipose-derived ECM; Device
Lead sponsor: Aegeria Soft Tissue LLC; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Fracture
Interventions: Arthrocentesis/PRP, Arthrocentesis/Saline; Biological · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Scar, Hypertrophic Scar, Mammary Disorder
Interventions: Botulinum Toxins, Normal saline; Drug · Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetic Foot Infection
Interventions: TP-102, Placebo; Biological · Other
Lead sponsor: Technophage, SA; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Webster, Texas

Conditions: Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Lung Cancer (Diagnosis)
Interventions: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Influenza
Interventions: VRC-FLUNPF0103-00-VP (H10ssF-6473); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psoriasis
Interventions: Med-Jet, Traditional Syringe; Device · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

Tele-Harm Reduction

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

Analyzing the Composition of Tears to Identify Cancer

Comparison of Articaine Mandibular Infiltration to Lidocaine Inferior Alveolar Nerve Block in Pediatric Patients

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis

Clinical Outcomes of Root Canal Treatment Using Modern Irrigation Protocols

Investigation of A-ECM for the Correction of Soft Tissue Defects

Platelet Rich Plasma Injection in Pilon Fractures

The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System